COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 2 for:    suvn-502
Previous Study | Return to List | Next Study

Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease (SUVN-502)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03564964
Expanded Access Status : Available
First Posted : June 21, 2018
Last Update Posted : September 24, 2019
Information provided by (Responsible Party):
Suven Life Sciences Limited

Tracking Information
First Submitted Date May 28, 2018
First Posted Date June 21, 2018
Last Update Posted Date September 24, 2019
Descriptive Information
Brief Title Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease
Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease. Investigator as well as the subject/caregiver must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria.

Subjects will not be evaluated for efficacy and safety during the expanded access.

Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Intermediate-size Population
Intervention Drug: SUVN-502
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Available
Contact: Ramakrishna Nirogi +91 9392483002
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT03564964
Responsible Party Suven Life Sciences Limited
Study Sponsor Suven Life Sciences Limited
Collaborators Not Provided
Investigators Not Provided
PRS Account Suven Life Sciences Limited
Verification Date September 2019